In response to the growing evidence of the detrimental effect that chlorofluorocarbons (CFCs) are having on the environment, 3M Pharmaceuticals and Glaxo have developed CFC-free systems for metered-dose inhalers used to treat asthma. Both systems use hydrofluoroalkane 134a (HFA-134a) as a propellant, and are currently in clinical trials.